Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Hematologic Malignancy Reports
Erschienen in: Current Hematologic Malignancy Reports 3/2013

01.09.2013 | Lymphomas (J Armitage, Section Editor)

Surveillance Imaging in Pediatric Hodgkin Lymphoma

verfasst von: Stephan D. Voss

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Children with Hodgkin Lymphoma (HL) routinely undergo surveillance computed tomography (CT) imaging for up to 5 years post-therapy (Rx), resulting in increased cost and radiation exposure without clear benefit. A number of recent studies have demonstrated that routine surveillance imaging, by CT, positron emission tomography (PET)/CT, as well as other imaging techniques, may be over-utilized for routine surveillance of patients with Hodgkin Lymphoma, and—in addition to contributing to increased cost and radiation exposure—show no clear survival benefit. The purpose of this review is to summarize recent data evaluating routine surveillance imaging and its role in detecting disease relapse in patients with Hodgkin Lymphoma.
Literatur
1.
Schwartz CL. Special issues in pediatric Hodgkin's disease. Eur J Haematol Suppl. 2005;66:55–62.PubMedCrossRef
2.
Smith MA et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. 2010;28(15):2625–34.PubMedCrossRef
3.
Freed J, Kelly KM. Current approaches to the management of pediatric Hodgkin lymphoma. Peadiatr Drugs. 2010;12(2):85–98.CrossRef
4.
Hodgson DC, Hudson MM, Constine LS. Pediatric hodgkin lymphoma: maximizing efficacy and minimizing toxicity. Semin Radiat Oncol. 2007;17(3):230–42.PubMedCrossRef
5.
Metzger ML, Hudson MM. Balancing efficacy and safety in the treatment of adolescents with Hodgkin's lymphoma. J Clin Oncol. 2009;27(36):6071–3.PubMedCrossRef
6.
Weiser DA, et al. Imaging in childhood cancer: a society for pediatric radiology and children's oncology group joint task force report. Pediatric blood & cancer. 2013.
7.
Mettler Jr FA et al. Radiologic and nuclear medicine studies in the United States and worldwide: frequency, radiation dose, and comparison with other radiation sources–1950–2007. Radiology. 2009;253(2):520–31.PubMedCrossRef
8.
•• Voss SD et al. Surveillance computed tomography imaging and detection of relapse in intermediate- and advanced-stage pediatric Hodgkin's lymphoma: a report from the Children's Oncology Group. J Clin Oncol. 2012;30(21):2635–40. This is a multi-center cooperative group study of over 200 patients with more than 8 years of follow-up, and is the first pediatric study to show no impact of surveillance imaging on overall disease survival in pediatric Hodgkin Lymphoma.PubMedCrossRef
9.
El-Galaly TC et al. Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs. Haematologica. 2012;97(6):931–6.PubMedCrossRef
10.
• Patel V, et al. Computed tomography and positron emission tomography/computed tomography surveillance after combined modality treatment of supradiaphragmatic Hodgkin lymphoma: a clinical and economic perspective. Leuk Lymphoma. 2013. An excellent overview of both PET and CT and their use in surveillance imaging, focusuing on both the clinical impact of surveillance imaging as well as the economic impact.
11.
•• Rathore N et al. Pediatric Hodgkin lymphoma: are we over-scanning our patients? J Pediatr Hematol Oncol. 2012;29(5):415–23. An excellent single institution retrospective study of pediatric Hodgkin Lymphoma patients looking systematically at radiation dose related to imaging studies versus the rate of relapse detection.CrossRef
12.
• Wagner-Johnston ND, Bartlett NL. Role of routine imaging in lymphoma. J Natl Compr Cancer Netw. 2011;9(5):575–84. quiz 585. A comprehensive review of routine imaging techniques commonly being used, including adult and pediatric work and both Hodgkin and non-Hodgkin lymphoma.
13.
Lister TA et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7(11):1630–6.PubMed
14.
Radford JA et al. Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records. BMJ. 1997;314(7077):343–6.PubMedCrossRef
15.
Torrey MJ, Poen JC, Hoppe RT. Detection of relapse in early-stage Hodgkin's disease: role of routine follow-up studies. J Clin Oncol. 1997;15(3):1123–30.PubMed
16.
Brenner DJ, Hall EJ. Computed tomography–an increasing source of radiation exposure. New Engl J Med. 2007;357(22):2277–84.PubMedCrossRef
17.
Pfannenberg AC et al. Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imaging. Br J Radiol. 2007;80(954):437–45.PubMedCrossRef
18.
Metzger ML et al. Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. JAMA. 2012;307(24):2609–16.PubMedCrossRef
19.
Kostakoglu L et al. Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? Leuk Lymphoma. 2012;53(11):2143–50.PubMedCrossRef
20.
Hartridge-Lambert SK et al. ABVD alone and a PET scan complete remission negates the need for radiologic surveillance in early-stage, nonbulky Hodgkin lymphoma. Cancer. 2013;119(6):1203–9.PubMedCrossRef
21.
Tebbi CK et al. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group. Pediatr Blood Canc. 2012;59(7):1259–65.CrossRef
22.
Ng A et al. ACR Appropriateness Criteria: follow-up of Hodgkin's lymphoma. Curr Probl Canc. 2010;34(3):211–27.CrossRef
23.
Dryver ET et al. Follow-up of patients with Hodgkin's disease following curative treatment: the routine CT scan is of little value. Br J Canc. 2003;89(3):482–6.CrossRef
24.
Schwartz C, et al. Predictors of early response and event-free survival in Hodgkin lymphoma (HL): PET versus CT imaging, in American Society of Clinical Oncology Annual Meeting. 2011, J Clin Oncol: Chicago, IL.Abstr 8006.
25.
26.
Kwee TC, et al. Whole-body diffusion-weighted imaging for staging malignant lymphoma in children. Pediatr Radiol. 2010.
27.
Punwani S et al. Diffusion-weighted MRI of lymphoma: prognostic utility and implications for PET/MRI? Eur J Nucl Med Mol Imag. 2013;40(3):373–85.CrossRef
28.
Platzek I et al. PET/MR for therapy response evaluation in malignant lymphoma: initial experience. Magma. 2013;26(1):49–55.PubMedCrossRef
29.
• Lin C et al. Whole-body diffusion magnetic resonance imaging in the assessment of lymphoma. Canc Imag. 2012;12:403–8. This is an up-to-date summary and review of the potential uses of MRI, diffusion imaging, and combined PET and MRI in evaluating patients with lymphoma.CrossRef
30.
El-Galaly T et al. Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: status in a single center. Leuk Lymphoma. 2011;52(4):597–603.PubMedCrossRef
31.
Moskowitz CH et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012;119(7):1665–70.PubMedCrossRef
32.
Devillier R et al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy. Haematologica. 2012;97(7):1073–9.PubMedCrossRef
33.
Lee AI et al. Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis. Cancer. 2010;116(16):3835–42.PubMedCrossRef
34.
Guadagnolo BA et al. Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease. J Clin Oncol. 2006;24(25):4116–22.PubMedCrossRef
35.
• Nievelstein RA et al. Radiation exposure and mortality risk from CT and PET imaging of patients with malignant lymphoma. Eur Radiol. 2012;22(9):1946–54. This is an interesting paper using Markov modeling techniques to evaluate the attribuatable risk resulting from radiation exposures that typically accompany diagnostic imaging procedures. This paper offers a balanced perspective to the discussion, and argues that the benefit of imaging may offset the modest additional attributable risk of radiation-related morbidity.PubMedCrossRef
36.
Hodgson DC et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol. 2007;25(12):1489–97.PubMedCrossRef
37.
van Leeuwen FE et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Canc Inst. 2003;95(13):971–80.CrossRef
38.
Inskip PD et al. Radiation dose and breast cancer risk in the childhood cancer survivor study. J Clin Oncol. 2009;27(24):3901–7.PubMedCrossRef
Metadaten
Titel
Surveillance Imaging in Pediatric Hodgkin Lymphoma
verfasst von
Stephan D. Voss
Publikationsdatum
01.09.2013
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 3/2013
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-013-0168-z

Weitere Artikel der Ausgabe 3/2013

Current Hematologic Malignancy Reports 3/2013 Zur Ausgabe

Lymphomas (P McLaughlin, Section Editor)

The Role of Radiation Therapy in the Treatment of Stage I-II Diffuse Large B-Cell Lymphoma

Lymphomas (J Armitage, Section Editor)

Hodgkin Lymphoma in Pregnancy

Lymphomas (C Dearden, Section Editor)

Post-Transplant Lymphoproliferative Disease (PTLD): Risk Factors, Diagnosis, and Current Treatment Strategies

Lymphomas (C Dearden, Section Editor)

Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Systematic Review of the Literature and Mini-Meta Analysis

Lymphomas (C Dearden, Section Editor)

T-Cell Receptor Signaling in Peripheral T-Cell Lymphoma – A Review of Patterns of Alterations in a Central Growth Regulatory Pathway

Lymphomas (P McLaughlin, Section Editor)

Treatment of Adolescents with Aggressive B-Cell Malignancies: The Pediatric Experience

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise